Download PDF
Arthritis und Rheuma 2006; 26(06): 381-385
DOI: 10.1055/s-0037-1620079
Kinderrheumatologie
Schattauer GmbH

Wachstumsstörungen bei Kindern mit juveniler idiopathischer Arthritis

Growth disturbance in children with juvenile idiopathic arthritis
Bechtold Susanne
1   Dr. von Haunersches Kinderspital der Ludwig-Maximilians Universität (Direktor: Prof. Dr. D. Reinhardt)
,
Dalla Pozza Robert
1   Dr. von Haunersches Kinderspital der Ludwig-Maximilians Universität (Direktor: Prof. Dr. D. Reinhardt)
,
Schwarz Hans Peter
2   Pädiatrische Endokrinologie und Diabetologie (Leitung: Prof. Dr. H. P. Schwarz)
› Author Affiliations
Further Information

Publication History

Publication Date:
23 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Störungen des Wachstums und der Knochenentwicklung sind bei Patienten mit juveniler idiopathischer Arthritis (JIA) wohl bekannt. Bei etwa elf Prozent der Patienten ist mit einer Endgröße unter -2 SD zu rechnen. Querschnittsstudien zeigten eine verminderte Kortikalisfläche neben einer erniedrigten Muskelfläche. Daher ist eine effektive Krankheitskontrolle mit möglichst geringen Glukokortikoiddosen anzustreben. Wachstumshormon stellt eine mögliche Therapieoption bei schweren Wachstumsstörungen dar. In einer kontrollierten Studie über vier Jahre konnten wir zeigen, dass es bei mit Wachstumshormon therapierten Patienten zu einer Größenzunahme von 1,0 SD kam, während die nicht therapierten Patienten 0,7 SD verloren. Unter Wachstumshormon kam es zu einer periostalen Knochenapposition und zu einer Zunahme der Muskulatur, was sich positiv auf die Knochenstabilität auswirken dürfte. Krankheitskontrolle durch ein aggressives Therapiemanagement kann Wachstumsstörungen bei Kindern mit JIA verringern. Wachstumshormon stellt dann eine mögliche zusätzliche Therapieoption dar, wenn weitere Störungen des Längenwachstums und der Knochenentwicklung bestehen.

Summary

Disturbance of growth and bone development are well known in children with juvenile idiopathic arthritis (JIA). About 11% of patients will reach a final height below –2 SD. Cross-sectional studies revealed a low cortical and muscle area. One treatment goal is therefore an effective disease control with glucocorticoids in a dose as low as possible. Growth hormone is a possible treatment option in patients with severe growth retardation. In a controlled study over a period of 4 years, there was an increase in height of 1.0 SD in growth hormone treated patients, whereas control patients lost 0.7 SD. In growth hormone treated patients there was periosteal bone apposition together with an increase in muscle mass, possibly indicative for an increase in bone stability. Disease control through an aggressive treatment regime may reduce growth impairment in children with JIA. Growth hormone might be an additive treatment option, if growth disturbance is still present.

Schlüsselwörter

Kleinwuchs - Osteoporose - Zytokine - Wachstumshormon

Keywords

Short stature - osteoporosis - cytokine - growth hormone
 

  • Literatur

  • 1 Aitman TJ., Palmer RG., Loftus J.. et al. Serum IGF-I levels and growth failure in juvenile chronic arthritis. Clin Exp Rheumatol 1989; 7: 557-61.
    PubMedGoogle Scholar
  • 2 Allen RC., Jimenez M., Cowell CT.. Insulin-like growth factor and growth hormone secretion in juvenile chronic arthritis. Ann Rheum Dis 1991; 50: 602-6.
    CrossrefPubMedGoogle Scholar
  • 3 Al-Mutair A., Bahabri S., Al-Mayouf S., Al-Ashwal A.. Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. J Pediatr Endocrinol Metab 2000; 13: 899-905.
    PubMedGoogle Scholar
  • 4 Bechtold S., Ripperger P., Bonfig W.. et al. Growth Hormone changes bone geometry and body composition in patients with juvenile idiopathic arthritis requiring glucocorticoid treatment: a controlled study using peripheral quantitative computed tomography. J Clin Endocrinol Metabolism 2005; 90: 3168-73.
    CrossrefPubMedGoogle Scholar
  • 5 Bechtold S., Ripperger P., Bonfig W.. et al. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years. J Rheumatol 2004; 31: 1407-12.
    Google Scholar
  • 6 Bechtold S., Ripperger P., Dalla Pozza R.. et al. Musculoskeletal and functional muscle-bone analysis in children with rheumatic disease using peripheral quantitative computed tomography. Osteoporos Int 2005; 16: 757-63.
    CrossrefPubMedGoogle Scholar
  • 7 Bechtold S., Ripperger P., Häfner R.. et al. Growth hormone therapy in juvenile idiopathic arthritis: 4 years data of a controlled study. J Pediatrics 2003; 143: 512-9.
    CrossrefPubMedGoogle Scholar
  • 8 Bechtold S., Ripperger P., Mühlbayer D.. et al. Growth hormone therapy in juvenile rheumatoid arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2001; 86: 5737-44.
    CrossrefPubMedGoogle Scholar
  • 9 Bennett AE., Silverman ED., Miller JJ., Hintz RL.. Insulin-like growth factors I and II in children with systemic onset juvenile arthritis. J Rheumatol 1988; 15: 655-8.
    Google Scholar
  • 10 Butenandt O.. Rheumatoid arthritis and growth retardation in children: treatment with human growth hormone. Eur J Pediatr 1979; 130: 15-28.
    CrossrefPubMedGoogle Scholar
  • 11 Cimaz R.. Osteoporosis in childhood rheumatic diseases: prevention and therapy. Best Practice & Research Clin Rheumatol 2002; 16: 397-409.
    Google Scholar
  • 12 Davies UM., Rooney M., Preece MA.. et al. Treatment of growth retardation in juvenile chronic arthritis with recombinant growth hormone. J Rheumatol 1994; 21: 153-8.
    Google Scholar
  • 13 De Benedetti F., Alonzi T., Moretta A.. et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor one. J Clin Invest 1997; 99: 643-50.
    CrossrefPubMedGoogle Scholar
  • 14 De Benedetti F., Meazza C., Olivieri M.. et al. Endocrinology. 2001; 142: 4818-26.
    PubMedGoogle Scholar
  • 15 Delharty PJD.. Interleukin-1 ß supresses growth hormone-induced acid-labile subunit mRNA levels and secretion in primary hepatocytes. Biochem Biophys Res Commun 1998; 243: 269-72.
    CrossrefPubMedGoogle Scholar
  • 16 Hendersson CJ., Specker BL., Sierra RI.. et al. Total body bone mineral content in non-corticosteroidtreated postpubertal females with juvenile rheumatoid arthritis. Arthritis Rheum 1999; 43: 531-40.
    Google Scholar
  • 17 Li P., Schwarz EM.. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003; 25: 19-33.
    CrossrefPubMedGoogle Scholar
  • 18 Liem JJ., Rosenberg AM.. Growth pattern in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: 663-8.
    PubMedGoogle Scholar
  • 19 Lovell DJ., White PH.. Growth and nutrition in juvenile rheumatoid arthritis. In Woo P., White PH., Ansell BM.. eds Pediatric Rheumatology Update. Oxford: Oxford University; 1990: 47-56.
    Google Scholar
  • 20 McRae VE., Farquharson C., Ahmed SF.. The pathophysiology of the growth plate in juvenile idiopathic arthritis. Rheumatology 2006; 45: 11-9.
    CrossrefPubMedGoogle Scholar
  • 21 Moe N., Rygg M.. Epidemiology of juvenile chronic arthritis in northern Norway: a ten year retrospective study. Clin Exp Rheumatol 1998; 16: 99-101.
    PubMedGoogle Scholar
  • 22 Roth J., Bechtold S., Borte G.. et al. Osteoporose bei juveniler idiopathischer Arthritis. Monatsschr. Kinderheilkd. 2006; 154: 456-64.
    Google Scholar
  • 23 Roth J., Palm C., Scheunemann I.. et al. Musculoskeletal abnormalities of the forearm in patients with juvenile idiopathic arthritis relate mainly to bone geometry. Arthritis Rheum 2004; 50: 1277-85.
    CrossrefPubMedGoogle Scholar
  • 24 Saha MT., Haapasaari J., Hannula S.. et al. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol 2004; 31: 1413-7.
    Google Scholar
  • 25 Simon D., Lucidarme N., Prieur AM.. et al. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003; 30: 2492-9.
    Google Scholar
  • 26 Simon D., Fernando K., Czernichow P., Prieur AM.. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002; 29: 1296-1300.
    Google Scholar
  • 27 Svantesson H.. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis. A pilot study. Clin Exp Rheumatol 1991; 9 (Suppl. 06) suppl 47-50.
    PubMedGoogle Scholar
  • 28 Touati G., Prieur AM., Ruiz JC., Noel M., Czernichow P.. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998; 83: 403-9.
    PubMedGoogle Scholar
  • 29 Truckenbrodt H., Häfner R.. Allgemeine und lokale Wachstumsstörungen bei chronischer Arthritis im Kindesalter. Schweiz Med Wschr 1991; 121: 608-20.
    PubMedGoogle Scholar
  • 30 Wang SJ., Yang YH., Lin YT.. et al. Attained adult height in juvenile rheumatoid arthritis with and without corticosteroid treatment. Clin Rheumatol 2002; 21: 363-8.
    CrossrefPubMedGoogle Scholar
  • 31 Yilmaz M., Kendirli SG., Altintas D.. et al. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001; 20: 30-5.
    PubMedGoogle Scholar
  • 32 Zak M., Hassager C., Lovell DJ etal.. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis. Arthritis Rheum 1999; 42: 790-8.
    CrossrefPubMedGoogle Scholar